Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Liver Extract–Folic Acid–Cyanocobalamin vs Placebo for Chronic Fatigue Syndrome

Liver Extract–Folic Acid–Cyanocobalamin vs Placebo for Chronic Fatigue Syndrome Abstract • Chronic fatigue syndrome is a recently defined entity for which clinical criteria were proposed by the Centers for Disease Control, Atlanta, Ga. A frequently advocated treatment in Southern California is an injectable solution of bovine liver extract containing follic acid and cyanocobalamin (LEFAC). We conducted a double-blind, placebo-controlled, crossover trial of intramuscular LEFAC in 15 patients who met the Centers for Disease Control criteria for chronic fatigue syndrome. Although patients responded to placebo and LEFAC by several criteria of functional status, no significant difference was apparent between response to placebo and that to LEFAC. The placebo response appeared to be strong. (Arch Intern Med. 1989;149:2501-2503) References 1. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition . Ann Intern Med . 1988;108:387-389.Crossref 2. Chisari FV. Regulation of human lymphocyte function by a soluble extract from normal human liver . J Immunol . 1978;121:1279-1286. 3. Schumacher K, Maerker-Alzer G, Wehmer U. A lymphocyte inhibition factor isolated from normal human liver . Nature . 1974;251:655-656.Crossref 4. Sakane T, Takada S, Kotani H, Tsunematsu T. Effects of methyl-B12 on the in vitro immune functions of human T lymphocytes . J Clin Immunol . 1982;2:101-109.Crossref 5. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer . In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents: Symposium, Microbiology Section, New York Academy of Medicine . New York, NY: Columbia University Press; 1949:191-206. 6. Jette AM, Davies AR, Cleary PD, et al. The functional status questionnaire: reliability and validity when used in primary care . J Gen Intern Med . 1986;1:143-149.Crossref 7. DuBois RE. Gamma globulin therapy for chronic mononucleosis syndrome . AIDS Res . 1986;2:S191-195.Crossref 8. Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebo-controlled trial . N Engl J Med . 1988;319:1692-1698.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Liver Extract–Folic Acid–Cyanocobalamin vs Placebo for Chronic Fatigue Syndrome

Loading next page...
 
/lp/american-medical-association/liver-extract-folic-acid-cyanocobalamin-vs-placebo-for-chronic-fatigue-xMVimIHk6n
Publisher
American Medical Association
Copyright
Copyright © 1989 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1989.00390110081017
Publisher site
See Article on Publisher Site

Abstract

Abstract • Chronic fatigue syndrome is a recently defined entity for which clinical criteria were proposed by the Centers for Disease Control, Atlanta, Ga. A frequently advocated treatment in Southern California is an injectable solution of bovine liver extract containing follic acid and cyanocobalamin (LEFAC). We conducted a double-blind, placebo-controlled, crossover trial of intramuscular LEFAC in 15 patients who met the Centers for Disease Control criteria for chronic fatigue syndrome. Although patients responded to placebo and LEFAC by several criteria of functional status, no significant difference was apparent between response to placebo and that to LEFAC. The placebo response appeared to be strong. (Arch Intern Med. 1989;149:2501-2503) References 1. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition . Ann Intern Med . 1988;108:387-389.Crossref 2. Chisari FV. Regulation of human lymphocyte function by a soluble extract from normal human liver . J Immunol . 1978;121:1279-1286. 3. Schumacher K, Maerker-Alzer G, Wehmer U. A lymphocyte inhibition factor isolated from normal human liver . Nature . 1974;251:655-656.Crossref 4. Sakane T, Takada S, Kotani H, Tsunematsu T. Effects of methyl-B12 on the in vitro immune functions of human T lymphocytes . J Clin Immunol . 1982;2:101-109.Crossref 5. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer . In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents: Symposium, Microbiology Section, New York Academy of Medicine . New York, NY: Columbia University Press; 1949:191-206. 6. Jette AM, Davies AR, Cleary PD, et al. The functional status questionnaire: reliability and validity when used in primary care . J Gen Intern Med . 1986;1:143-149.Crossref 7. DuBois RE. Gamma globulin therapy for chronic mononucleosis syndrome . AIDS Res . 1986;2:S191-195.Crossref 8. Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome: lack of efficacy in a placebo-controlled trial . N Engl J Med . 1988;319:1692-1698.Crossref

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Nov 1, 1989

References